Literature DB >> 15883268

Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability.

Alexandre Prat1, Katarzyna Biernacki, Tanya Saroli, John E Orav, Charles R G Guttmann, Howard L Weiner, Samia J Khoury, Jack P Antel.   

Abstract

BACKGROUND: We have previously shown that the inducible kinin B(1) receptor is expressed on T lymphocytes during relapses and progression in multiple sclerosis.
OBJECTIVE: To evaluate the correlation between the expression of B1 receptor on peripheral blood mononuclear cells derived from patients who have multiple sclerosis with serial, clinical magnetic resonance imaging and immunological study-derived measures.
DESIGN: Using frozen samples obtained from a high-frequency magnetic resonance imaging-immunological study, we analyzed B1 receptor messenger RNA (mRNA) expression in peripheral blood-derived mononuclear cells serially collected from 6 patients with multiple sclerosis and 8 healthy control subjects by semiquantitative radioactive duplex reverse transcriptase-polymerase chain reaction amplification. Time-course kinin B1-actin mRNA ratios were subsequently compared with corresponding clinical magnetic resonance imaging and immune parameters.
RESULTS: The time-course kinin B1-actin mRNA ratio correlated positively with the Expanded Disability Status Scale index (P<.001), occurrence of clinical relapse (P = .02), volume of lesion on T2-weighted images (P<.003) and interleukin 2 receptor and major histocompatibility complex class II expression on CD4+ lymphocytes, but not with gadolinium-enhancing lesions. The time-course kinin B1-actin mRNA ratios were 5 to 25 times lower in samples derived from healthy controls.
CONCLUSION: The correlation of kinin B1 receptor mRNA levels with dynamic clinical and magnetic resonance imaging measures suggests that expression of this receptor can serve as an index of disease activity in multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15883268     DOI: 10.1001/archneur.62.5.795

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  12 in total

1.  Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system.

Authors:  Ulf Schulze-Topphoff; Alexandre Prat; Timour Prozorovski; Volker Siffrin; Magdalena Paterka; Josephine Herz; Ivo Bendix; Igal Ifergan; Ines Schadock; Marcelo A Mori; Jack Van Horssen; Friederike Schröter; Alina Smorodchenko; May Htwe Han; Michael Bader; Lawrence Steinman; Orhan Aktas; Frauke Zipp
Journal:  Nat Med       Date:  2009-06-28       Impact factor: 53.440

Review 2.  [Coagulation factors and multiple sclerosis : Key factors in the pathogenesis?]

Authors:  K Göbel; C Kleinschnitz; S G Meuth
Journal:  Nervenarzt       Date:  2018-08       Impact factor: 1.214

3.  Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release.

Authors:  Kerstin Göbel; Chloi-Magdalini Asaridou; Monika Merker; Susann Eichler; Alexander M Herrmann; Eva Geuß; Tobias Ruck; Lisa Schüngel; Linda Groeneweg; Venu Narayanan; Tilman Schneider-Hohendorf; Catharina C Gross; Heinz Wiendl; Beate E Kehrel; Christoph Kleinschnitz; Sven G Meuth
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-17       Impact factor: 11.205

Review 4.  Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms.

Authors:  Amaly Nokkari; Hadi Abou-El-Hassan; Yehia Mechref; Stefania Mondello; Mark S Kindy; Ayad A Jaffa; Firas Kobeissy
Journal:  Prog Neurobiol       Date:  2018-01-31       Impact factor: 11.685

5.  Fusion of metabolomics and proteomics data for biomarkers discovery: case study on the experimental autoimmune encephalomyelitis.

Authors:  Lionel Blanchet; Agnieszka Smolinska; Amos Attali; Marcel P Stoop; Kirsten A M Ampt; Hans van Aken; Ernst Suidgeest; Tinka Tuinstra; Sybren S Wijmenga; Theo Luider; Lutgarde M C Buydens
Journal:  BMC Bioinformatics       Date:  2011-06-22       Impact factor: 3.169

6.  The role of kinin receptors in preventing neuroinflammation and its clinical severity during experimental autoimmune encephalomyelitis in mice.

Authors:  Rafael C Dutra; Daniela F P Leite; Allisson F Bento; Marianne N Manjavachi; Eliziane S Patrício; Cláudia P Figueiredo; João B Pesquero; João B Calixto
Journal:  PLoS One       Date:  2011-11-22       Impact factor: 3.240

7.  Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis.

Authors:  Rohit Bakshi; Ada Yeste; Bonny Patel; Shahamat Tauhid; Subhash Tummala; Roya Rahbari; Renxin Chu; Keren Regev; Pia Kivisäkk; Howard L Weiner; Francisco J Quintana
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-01-27

Review 8.  Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models.

Authors:  Nemat Khan; Maree T Smith
Journal:  Inflammopharmacology       Date:  2014-02       Impact factor: 4.473

9.  Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells.

Authors:  Kerstin Göbel; Susann Pankratz; Chloi-Magdalini Asaridou; Alexander M Herrmann; Stefan Bittner; Monika Merker; Tobias Ruck; Sarah Glumm; Friederike Langhauser; Peter Kraft; Thorsten F Krug; Johanna Breuer; Martin Herold; Catharina C Gross; Denise Beckmann; Adelheid Korb-Pap; Michael K Schuhmann; Stefanie Kuerten; Ioannis Mitroulis; Clemens Ruppert; Marc W Nolte; Con Panousis; Luisa Klotz; Beate Kehrel; Thomas Korn; Harald F Langer; Thomas Pap; Bernhard Nieswandt; Heinz Wiendl; Triantafyllos Chavakis; Christoph Kleinschnitz; Sven G Meuth
Journal:  Nat Commun       Date:  2016-05-18       Impact factor: 14.919

10.  Biotechnological Fluorescent Ligands of the Bradykinin B1 Receptor: Protein Ligands for a Peptide Receptor.

Authors:  Xavier Charest-Morin; François Marceau
Journal:  PLoS One       Date:  2016-02-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.